Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipratropium + terbutaline
- Development stage
- Preclinical
- Lead developer
- Boehringer
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
A combination bronchodilator therapy consisting of ipratropium, an anticholinergic agent, and terbutaline, a short-acting β2-agonist. This combination works through complementary mechanisms to provide bronchodilation in respiratory conditions. Ipratropium antagonizes muscarinic acetylcholine receptors, inhibiting the parasympathetic nervous system in the airways, while terbutaline stimulates β2-adrenergic receptors to relax bronchial smooth muscle.
- Brand names
- AtroventBricanyl
- Other names
- ipratropium bromide + terbutaline sulfate
02
Targets
M1 (Muscarinic acetylcholine receptor M1)ADRB2 (β2)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on ipratropium + terbutaline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipratropium + terbutaline.